Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of several tumours [1] [2] [3] [4] , which rely on the constitutive engagement of this pathway for their growth and survival 1, 5 . However, MET is expressed not only by cancer cells but also by tumour-associated stromal cells, although its precise role in this compartment is not well characterized [6] [7] [8] [9] [10] [11] . Here we show that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor (HGF). Met deletion in mouse neutrophils enhances tumour growth and metastasis. This phenotype correlates with reduced neutrophil infiltration to both the primary tumour and metastatic sites. Similarly, Met is necessary for neutrophil transudation during colitis, skin rash or peritonitis. Mechanistically, Met is induced by tumourderived tumour necrosis factor (TNF)-a or other inflammatory stimuli in both mouse and human neutrophils. This induction is instrumental for neutrophil transmigration across an activated endothelium and for inducible nitric oxide synthase production upon HGF stimulation. Consequently, HGF/MET-dependent nitric oxide release by neutrophils promotes cancer cell killing, which abates tumour growth and metastasis. After systemic administration of a MET kinase inhibitor, we prove that the therapeutic benefit of MET targeting in cancer cells is partly countered by the pro-tumoural effect arising from MET blockade in neutrophils. Our work identifies an unprecedented role of MET in neutrophils, suggests a potential 'Achilles' heel' of MET-targeted therapies in cancer, and supports the rationale for evaluating anti-MET drugs in certain inflammatory diseases.
Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of several tumours [1] [2] [3] [4] , which rely on the constitutive engagement of this pathway for their growth and survival 1, 5 . However, MET is expressed not only by cancer cells but also by tumour-associated stromal cells, although its precise role in this compartment is not well characterized [6] [7] [8] [9] [10] [11] . Here we show that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor (HGF). Met deletion in mouse neutrophils enhances tumour growth and metastasis. This phenotype correlates with reduced neutrophil infiltration to both the primary tumour and metastatic sites. Similarly, Met is necessary for neutrophil transudation during colitis, skin rash or peritonitis. Mechanistically, Met is induced by tumourderived tumour necrosis factor (TNF)-a or other inflammatory stimuli in both mouse and human neutrophils. This induction is instrumental for neutrophil transmigration across an activated endothelium and for inducible nitric oxide synthase production upon HGF stimulation. Consequently, HGF/MET-dependent nitric oxide release by neutrophils promotes cancer cell killing, which abates tumour growth and metastasis. After systemic administration of a MET kinase inhibitor, we prove that the therapeutic benefit of MET targeting in cancer cells is partly countered by the pro-tumoural effect arising from MET blockade in neutrophils. Our work identifies an unprecedented role of MET in neutrophils, suggests a potential 'Achilles' heel' of MET-targeted therapies in cancer, and supports the rationale for evaluating anti-MET drugs in certain inflammatory diseases.
To ensure Met deletion in the immune system only, we took advantage of the Tie2:Cre deleter that excises floxed genes in both bone marrow and endothelial cells 12 , and we reconstituted lethally irradiated C57BL/6 wild-type (WT) mice with bone marrow cells from Tie2;Met wt/wt (WT) or Tie2;Met fl/fl (knockout (KO)) mice (Extended Data Fig. 2a ), producing WTRWT or KORWT mice, respectively. Compared to WTRWT controls, both growth and metastatic burden of subcutaneous LLC lung carcinomas were boosted in KORWT mice ( Fig. 1a-g) , with reduced tumour apoptosis and necrosis, increased proliferation, but comparable vessel parameters and hypoxia (Extended Data Fig. 2b-r) . A similar induction in tumour growth and metastasis was observed in non-irradiated KO versus WT mice (Extended Data Fig. 2s-u) , but tumour growth, as well as the vascular features, were comparable in WTRWT versus WTRKO chimaeras, displaying Met deletion in endothelial cells only (Extended Data Fig.  2o -r, v). Thus, Met deletion in immune cells favours cancer growth and metastasis.
Blood counts and percentage of circulating blood cell subsets did not change in WTRWT and KORWT mice, either at baseline or upon LLC tumour engraftment (Extended Data Fig. 3a -e and Extended Data Tables 1, 2) . Notably, KORWT mice displayed reduced numbers of tumour-infiltrating CD45 1 leukocytes and, among all the different subpopulations, only Ly6G 1 tumour-associated neutrophils (TANs) were strongly reduced in KORWT versus WTRWT mice at any time point ( Fig. 1h-j and Extended Data Fig. 3f-k) . Similarly, lungs from KORWT tumour-bearing mice contained fewer CD45 1 leukocytes with decreased Ly6G 1 neutrophil infiltration, whereas the number of F4/80 1 macrophages was comparable ( Fig. 1k -m and Extended Data Fig. 3l, m) . Furthermore, reconstitution of Met in neutrophils only 13 (Extended Data Fig. 4a, b ) was sufficient to rescue their recruitment and to hinder tumour growth and metastasis in KORWT mice ( Fig. 1n-q) . Vice versa, restricted deletion of Met in neutrophils (Mrp8;Met fl/fl ) by the neutrophil-specific Mrp8:Cre line 13 (Extended Data Fig. 4c, d ) led to enhanced tumour growth and dissemination, and marked TAN reduction, as in KORWT chimaeras (Fig. 1r-u and Extended Data Fig. 4e ). These results indicate that MET is required for recruiting anti-tumoural neutrophils.
To extend our findings to other tumour types, we proved that Met deletion in the haematopoietic system increased the growth of (1) orthotopic T241 fibrosarcomas and B16F10 melanomas, (2) spontaneous mammary tumours in MMTV-PyMT 1 transgenic mice, (3) H-Ras(G12V)-and c-Myc-driven hepatocellular carcinomas (HCCs), and (4) chemically induced colorectal cancers (CRCs) ( Fig. 2a-j and Extended Data Fig. 5a, b ). Furthermore, lung colonization of B16F10 melanoma cells (from either the primary tumour or after cancer cell intravenous injection) and of MMTV-PyMT 1 breast tumours was boosted in Met KO chimaeras (Fig. 2k , l and Extended Data Fig. 5c ). In all these tumour types, Met KO TANs were fewer than WT TANs ( Fig. 2m and Extended Data Fig. 5d , e). Interestingly, during chronic bowel inflammation (preceding CRC formation), neutrophil but not macrophage infiltration of the colon was also abated by haematopoietic Met deletion, but this reduction did not impinge on colitis severity (Extended Data Fig. 5f -i). B16F10 melanomas and HCCs displayed enhanced tumour growth (and metastasization) as well as reduced TAN infiltration in Mrp8;Met fl/fl versus Mrp8;Met wt/wt mice ( Fig. 2n-q) . Conversely, orthotopic Panc02 carcinomas grew and metastasized similarly in both WTRWT and KORWT mice, and TAN infiltration did not change (Extended Data Fig. 5j-l) . However, these tumours produced little HGF compared to LLC tumours (Extended Data Fig. 5m, n) . In general, plasma and intratumour HGF did not differ between genotypes (Extended Data Fig. 5o, p) . In sum, Met deficiency in neutrophils promotes the progression of different (HGF-secreting) tumours.
Systemic treatment of WT mice carrying B16F10 melanomas (which are dependent on MET 14 ) with three different MET tyrosine-kinase inhibitors (PF-04217903, INCB28060 and JNJ-38877605), strongly reduced TAN recruitment (Extended Data Fig. 5q ). We then compared MET silencing in cancer cells versus systemic MET inhibition. Systemic administration of PF-04217903 decreased the weight and volume of B16F10 melanomas by 36% and 54%, respectively. Instead, MET knockdown in cancer cells only, led to 58% and 75% inhibition of tumour growth and volume (Fig. 2r, s and Extended Data Fig. 5r ). However, the combination of these two strategies was not synergic but dampened tumour inhibition to the same level as observed with PF-04217903 alone (Fig. 2r, s) . TAN inhibition by PF-04217903 was comparable in both Met-silenced and scrambled B16F10 melanomas (Fig. 2t ). These data unveil how the therapeutic benefit of systemic MET inhibition is partly blunted by the blockade of anti-tumoural neutrophils.
To date, MET expression in neutrophils has been poorly documented 11 . We thus measured MET levels in circulating or tumour-infiltrating neutrophils. Circulating Ly6G 1 cells from healthy mice expressed low MET, but these levels were increased in circulating neutrophils from LLC-tumour-bearing mice and even further in TANs (Fig. 3a, b and Extended Data Fig. 6a ). Similarly, neutrophils isolated from non-small-cell lung tumours displayed much higher MET levels than in the healthy tissue ( Fig. 3c ).
Co-culture with interleukin (IL)-1a pre-activated endothelium as well as stimulation with tumour-or cancer-cell-conditioned medium (TCM or CCM, respectively) promoted MET expression in both mouse and human neutrophils ( Fig. 3d-g) . In a biased approach [15] [16] [17] , we found that TNF-a and lipopolysaccharide (LPS) (but not IL-1a, HGF, or hypoxia) induced MET expression in both mouse and human neutrophils ( Fig. 3h and Extended Data Fig. 6b -e; data not shown). TNF-a-mediated MET induction required TNFR1 and subsequent nuclear factor (NF)-kB activation ( Fig. 3i-k ). TNF-a alone was not able to trigger either MET phosphorylation or HGF release in neutrophils (Extended Data Fig. 6f -h).
Silencing of endothelial-cell-borne TNF-a (which is 250-fold increased upon stimulation with IL-1a; Extended Data Fig. 6i ), knockout of neutrophil-borne TNFR1 (but not of TNFR2), and pharmacological blockade of TNF-a with the TNF-a-trap Enbrel, prevented MET induction in mouse or human neutrophils upon co-culture with activated endothelial cells or exposure to TCM/CCM ( Fig. 3l and Extended Data Fig. 6j -m). Finally, systemic administration of Enbrel in LLC-tumour-bearing mice diminished MET expression in neutrophils as well, resulting in their reduced recruitment to the tumour (Fig. 3m, n) . Although MET is scarcely expressed in naive neutrophils, it is strongly induced by inflammatory stimuli.
Mechanistically, impaired TAN accumulation after Met inactivation was not due to cell death as assessed in LLC tumours and in culture, both at baseline and under LPS stimulation, with or without HGF (Extended Data Fig. 7a-e ), but rather to a defect in neutrophil recruitment from the blood. Indeed, also in the case of acute inflammation, Met KO neutrophils displayed reduced exudation to the skin or to the peritoneal cavity ( Fig. 4a-d and Extended Data Fig. 8a, b ). Macrophage and lymphocyte recruitment did not change ( Fig. 4d and Extended Data Fig. 8c, d ). Vice versa, recombinant HGF recruited WT neutrophils inside subcutaneous air pouches with similar efficacy to the neutrophil chemoattractant CXCL1 ( Fig. 4e and Extended Data Fig. 8e ). In contrast, Met KO neutrophils did not migrate towards HGF, although their response to CXCL1 was preserved ( Fig. 4e and Extended Data Fig. 8e ). Mirroring this approach, an anti-HGF blocking antibody 18 prevented neutrophil infiltration to tumours and inflamed skin ( Fig. 4f ).
We then tested the relevance of MET for neutrophil migration. Stimulation of WT neutrophils with HGF promoted their adhesion and chemotaxis through an activated endothelium whereas Met KO 
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neutrophils (displaying an 85% reduction in MET protein levels compared to WT; Extended Data Fig. 2a ) completely lost this response (Fig. 4g , h and Extended Data Fig. 8f ). In line with this, TCM (containing 2.6 6 0.3 ng ml 21 HGF) promoted transendothelial migration of WT neutrophils, but its effect was 43% lower on Met KO neutrophils ( Fig. 4i ). Upon HGF neutralization, WT neutrophils responded to TCM only partially, as did Met KO neutrophils ( Fig. 4i ). Neither HGF nor TCM influenced neutrophil behaviour on non-activated endothelial cells or bare membranes (Extended Data Fig. 8f-h ). Hence, HGF-mediated MET activation is required for neutrophil transendothelial migration to the inflammatory site.
Once migrated inside the tumour, N1 or N2 neutrophils can inhibit or favour tumour progression, respectively 19 . Among the N1 and N2 genes, only the expression of the N1 marker inducible nitric oxide synthase (Nos2, also known as iNos) was lower in Met KO versus WT TANs but similar in macrophages ( Fig. 4j and Extended Data Fig. 8i ). Compared to WTRWT mice, tumours harvested from KORWT mice displayed reduced nitric oxide (NO) production and 3-nitrotyrosine (3NT) formation, a sign of NO-mediated cell damage ( Fig. 4k-n) . In vitro, Met KO TANs had lower cancer-cell-killing capacity than WT TANs; iNOS inhibition by N G -monomethyl-L-arginine (L-NMMA) blunted this difference ( Fig. 4o and Extended Data Fig. 8j ). HGF-stimulated WT but not Met KO neutrophils displayed enhanced NO release and cytotoxicity, which was abated by L-NMMA (Extended Data Fig. 8k , l). We then hypothesized that HGF/MET pathway is key for antitumoural neutrophils only. Neutrophil depletion in WTRWT chimaeras did not affect LLC tumour growth, implying that in this tumour model anti-tumoural and pro-tumoural neutrophils are in balance ( Fig. 4p-r) . The same treatment in KORWT mice reduced tumour growth by 34% ( Fig. 4p-r) , indicating that Met deletion inhibits recruitment and activation of cytotoxic, but not of pro-tumoural neutrophils, which are instead blocked by the anti-Ly6G antibody ( Fig. 4r and Extended Data Fig. 8m ).
In sum, we demonstrate that MET is induced by inflammatory stimuli. This receptor is then required for neutrophil extravasation to inflamed tissues. Extravasated neutrophils respond to HGF by producing cytotoxic nitric oxide (Extended Data Fig. 1 ). All these steps restrain non-specific immune reactions to the inflammatory site, preventing damage of healthy organs.
These findings highlight a double-edged role of MET in cancer: on the one hand, in MET-addicted tumours, this pathway is vital for the cell cycle and survival 2 ; on the other hand, it promotes anti-tumorigenic activities in neutrophils. Thus, alternative approaches targeting MET on cancer cells only, and trials guided by new patient selection strategies will be important to maximize the efficacy of MET inhibition in oncological diseases 3, 4, 20 .
Finally, given the fact that MET-inhibiting drugs are not associated with overt toxicity 1 , MET-targeted therapies might ameliorate the symptoms of inflammatory disorders in which neutrophils are important for disease pathogenesis 21 .
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METHODS
Animals. The Met floxed mice, a gift from S. S. Thorgeirsson, were backcrossed in a C57BL/6 background. The Tie2:Cre and MMTV-PyMT transgenic lines were obtained from our mouse facility. The Mrp8:Cre mice were a gift from C. A. Lowell and P. Bruhns 13, [22] [23] [24] [25] [26] . C57BL/6 mice were purchased from Harlan. TNFR1 KO mice and TNFR2 KO mice were a gift from C. Libert. The Met floxed mice were intercrossed for at least two generations with Tie2:Cre or Mrp8:Cre in order to obtain Met fl/fl Cre-negative (WT) or Met fl/fl Cre-positive (KO) littermates for the specific promoter. All the experimental procedures were approved by the Institutional Animal Care and Research Advisory Committee of the KU Leuven. In all the experiments, mice were gender and age matched (within an age range between 6 and 10 weeks). Cell lines. Murine Lewis lung carcinoma cells (LLC), melanoma B16F10, and human non-small-cell lung carcinoma A549 cells were obtained from the American Type Culture Collection (ATCC); the murine pancreatic tumour cell line Panc02 and the murine fibrosarcoma cell line T241 were gifts from U. Cavallaro and L. Claesson-Welsh, respectively. LLC, B16F10, A549 and T241 cells were cultured in DMEM (Gibco) supplemented with 2 mM glutamine, 100 units ml 21 penicillin, 100 mg ml 21 streptomycin and containing 10% FBS (DMEM 10% FBS). Panc02 cells were cultured in RPMI (Gibco) supplemented with 2 mM glutamine, 100 units ml 21 penicillin, 100 mg ml 21 streptomycin and containing 10% FBS. All these murine tumour cell lines are syngeneic in a C57BL/6 background, allowing implantation in Met conditional knockout mice or chimaeras. HUVECs were isolated from human umbilical cords and maintained in M199 (Invitrogen) supplemented with 20% FBS, 2 mM glutamine, 100 units ml 21 penicillin, 100 mg ml 21 streptomycin, 0.15% heparin, 20 mg ml 21 ECGS (M199 complete). 0.1% pork gelatin was used to favour the adhesion of HUVECs to the flask bottom. All cells were maintained in a humidified incubator in 5% CO 2 and 95% air at 37 uC. Three or four different shRNA lentiviral vectors (Sigma) were used to silence Met in LLC, B16F10 or T241 cells (LLC shMet, B16F10 shMet or T241 shMet; see later), or to silence TNFA in HUVECs (HUVEC shTNFA). Scramble lentiviral vectors were used as control. Transduced cells were selected with 8 mg ml 21 puromycin. All cancer cell lines and primary HUVECs underwent mycoplasma testing before their use. Negative mycoplasma contamination status was verified using LookOut Mycoplasma PCR Kit (Sigma) and MycoAlert Mycoplasma Detection Kit plus Assay Control (Lonza). Panc02 and T241 cells were both authenticated by Idexx Bioresearch. All cells were passaged in the laboratory for no longer than 6 months after receipt. Supplementary Table 1 lists the sequences of all the shRNA constructs used in this study. Bone marrow transplantation and blood cell count. Recipient 6-week-old female mice were lethally irradiated (9.5 Gy) and then intravenously injected with 10 7 bone marrow cells from WT or KO mice 16 h later. Experiments were initiated 5 weeks after bone marrow reconstitution. Blood cell count was determined using a haemocytometer on peripheral blood collected by retro-orbital bleeding. Haematopoietic stem/progenitor cell transduction. For MET overexpression or reconstitution in WT or Met KO neutrophils, respectively, lineage-negative haematopoietic stem/progenitor cells (HSPCs) were enriched with the mouse haematopoietic progenitor enrichment kit (Stem Cell Technologies) and checked for purity by FACS according to the manufacturer's protocol. 1 3 10 6 cells ml 21 were pre-stimulated for 5 h with stem span serum-free medium (Stem Cell Technologies) supplemented with IL-3 (20 ng ml 21 ), SCF (100 ng ml 21 ), TPO (100 ng ml 21 ) and FLT-3L (100 ng ml 21 ) (Promega), and transduced with 1 3 10 8 transducing units (TU) ml 21 of a lentiviral vector expressing mouse Met under the promoter of the human gene S100A8 (Mrp8:Met), which has been engineered for neutrophil-specific transcriptional targeting, or an empty vector (Mrp8:Empty) as control. Briefly, the promoter driving Met expression in neutrophils only corresponds to a 3.6 kb DNA fragment encompassing the natural 59 and 39 regulatory regions but deleted of its exon coding sequences. Hence, Met is under the control of the 59 and 39 untranslated regions of the human S100A8 gene and other proximal cis regulatory sequences present in the surrogate DNA fragment 13, [22] [23] [24] [25] [26] . Ten hours after the first viral transduction, cells received a second round of their respective lentiviral vector; 7 h later 1 3 10 6 cells were injected via tail vein in lethally irradiated C57BL/6 recipient mice. A fraction of transduced HSPCs were cultured and collected after 9 days to measure the number of integrated vector copies per cell genome (vector copy number (VCN)) by qPCR using custom TaqMan assays specific for HIV gag sequences (Applied Biosystems), as previously described 27 . Standard curves for HIV gag (contained by both Mrp8:Empty and Mrp8:Met lentiviral vectors) were obtained from the corresponding plasmids. Fifty nanograms of genomic DNA from each sample were subjected to qPCR in quadruplicate using an ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems). VCN was determined comparing the amplification signal on the genomic DNA with the standard curve consisting of serial dilutions over a 6 log range (slope, approximately 23.3; intercept, approximately 35; efficiency percent-age, approximately 100). Average copies per cell genome were calculated taking into account that one murine diploid genome 5 5.92 pg. The results of this analysis are shown in Supplementary Table 2 . Tumour models. 2 3 10 6 LLC or 1 3 10 6 B16F10 cells were injected subcutaneously while 2 3 10 6 T241 cells were injected intradermally in a volume of 200 ml PBS. Tumour volumes were measured three times a week with a calliper. At end stage, tumours were weighed and collected for histological examination or FACS analysis. MMTV-PyMT 1 spontaneous breast tumours were measured 10 weeks after birth (6 weeks after bone marrow transplantation), three times a week, and mice were killed at week 16. Lung metastases were contrasted by intratracheal injection of a 15% India ink solution, by H&E staining on lung paraffin sections, or detected by qRT-PCR for the melanoma-specific gene S100B in the models involving B16F10 cells. For orthotopic pancreatic tumour growth, mice were anaesthetized with isoflurane, the stomach exteriorized via abdominal midline incision, and 1 3 10 6 Panc02 tumour cells in 30 ml PBS were injected into the head of the pancreas using a 29-gauge needle. A successful intrapancreatic injection of tumour cells was identified by the appearance of a fluid bleb without intraperitoneal leakage. Mice displaying peritoneal leakage were immediately killed and excluded from the analysis. At day 12, primary tumours were removed and weighed. Enlarged lymph nodes were counted under a stereoscopic microscope. For the chemically induced colorectal cancer model, body-weight-matched mice received one intraperitoneal injection of 10 mg kg 21 of azoxymethane (AOM) followed by 3 cycles of 7 days of 1.5% (cycle I) or 1.7% (cycle II-III) dextran sodium sulphate (DSS) in drinking water, starting from the day of AOM injection 28 . After 160 days, the colon was collected and prepared for histological evaluation with the 'Swiss roll' technique 29 . For the oncogene-driven hepatocellular carcinoma model, mice received a 1:1 molar ratio (3 mg total DNA) of piggyBac transposons encoding for c-Myc and H-Ras G12V oncogenes, driven by the PGK promoter, together with the hyperactive piggyBac transposase-encoding plasmid 30 . DNA solutions containing transposon/transposase plasmids were diluted in 2 ml of Ringer's solution and hydrodynamically delivered in 7 s through the tail vein. Mice were killed 24 weeks after the hydrodynamic injection. Lung colonization assay. In the experimental metastasis assays, 0.5 3 10 6 B16F10 cells were injected in the tail vein and lungs were collected after 12 days. To quantify pulmonary seeding, lungs were homogenized in Trizol (Ambion) and RNA was purified with the RNeasy Mini kit (Ambion) according to manufacturer's instructions. The expression of the melanocyte-specific gene S100B was measured as a readout of lung colonization by qRT-PCR following reverse transcription to complementary DNA with the QuantiTect Reverse Transcription kit (Qiagen). Mice treatments. To induce chronic colitis, mice received 3 cycles of 7 days of 1.5% (cycle I) or 1.7% (cycle II-III) DSS in drinking water; 2 weeks after the last DSS cycle, the colon was collected and prepared for histological evaluation as described earlier 29 . For in vivo MET inhibition, B16F10 tumour-bearing mice received 40 mg kg 21 PF-04217903 (AbMole Bioscience) or the corresponding vehicle (0.5% methylcellulose in saline) via oral gavage every day once a day starting from day 2 after tumour injection and twice a day from day 11 until the end of the experiment; alternatively mice were treated with 50 mg kg 21 INCB28060 (AbMole Bioscience) or 50 mg kg 21 JNJ-38877605 (Selleckchem). For TNF-a inhibition in vivo, LLC tumour-bearing mice were randomized for comparable tumour volumes at the end stage and intraperitoneally (i.p.) injected with 10 mg kg 21 of Enbrel or human IgG in PBS, 3 and 1 day before tumour collection. For HGF inhibition in vivo, LLC tumour-bearing mice were randomized when average tumour volume was 300 mm 3 and i.p. injected with 0.2 mg per mouse of anti-HGF blocking antibody (AF-2207, R&D 18,31 ) or goat IgG in PBS. Tumours were collected 20 h later for histological analysis; 12-O-tetradecanoylphorbol-13-acetate (TPA) ear painting was done 5 h after antibodies administration and ears were collected 15 h later. For neutrophil depletion, mice were treated with 50 mg per 20 g body weight of rat anti-mouse Ly6G antibody (clone 1A8, BioXCell) or rat IgG every second day starting from day 4 after LLC tumour injection and every day from day 12 after tumour injection until the end of the experiment. Efficiency of neutrophil depletion was assessed by FACS in blood and tumours. TPA model of acute skin inflammation. Phorbol ester TPA was used to induce acute skin inflammation as described previously 32 . Briefly, TPA (2.5 mg in 20 ml acetone per mouse) was topically applied on the ear skin of anaesthetized mice. The contralateral ear was painted with acetone alone as vehicle control. Mice were killed after 24 h and ears were collected in 2% PFA for histological analysis. Zymosan-mediated acute peritonitis model. To induce acute peritonitis, zymosan A (Sigma) was prepared at 2 mg ml 21 in sterile PBS. Four hours after i.p. injection of 0.1 mg zymosan A per mouse, inflammatory exudates were harvested by peritoneal lavage with 2 ml PBS. Cells were counted with a Burker chamber and stained for Ly6G (1A8) and F4/80 (BM8) for FACS analysis.
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Air pouch assay. To create subcutaneous air pouches, bone marrow transplanted chimaeric mice or Mrp8;Met fl/fl or Mrp8;Met wt/wt mice were injected with 3 ml of sterile air by dorsal subcutaneous injection with a butterfly 23 G needle on day 0 and on day 3. On day 6, 200 ng per mouse of murine CXCL1 or HGF dissolved in 0.5 ml PBS-Heparin (15 U ml 21 ) or PBS-Heparin (15 U ml 21 ) as control, were injected in the newly formed dorsal camera. After 4 h, inflammatory cells were harvested by washing the pouch with 5 ml of PBS. Cells were stained for Ly6G (1A8), washed and resuspended in PBS 0.1% BSA with unlabelled counting beads and quantified by FACS.
Mouse white blood cell isolation. Blood was collected from the retro-orbital vein in 10% heparin. For the isolation of white blood cells (WBCs), the blood was diluted in 1.25% dextran in saline to allow the sedimentation of red blood cells (RBCs). After 30 min, the erythrocyte-poor upper layer was collected and washed in PBS 0.1% BSA. The remaining RBCs were lysed in a hypotonic solution of 0.2% NaCl for 30 s and brought in isotonic condition with 1.6% NaCl and 0.1% glucose. WBCs were washed in PBS 0.1% BSA, counted and resuspended accordingly with the experimental setting. Mouse blood neutrophil isolation. Blood was collected from the retro-orbital vein in 10% heparin and diluted in an equal volume of PBS 0.5% BSA. Up to 5 ml of diluted blood was layered on top of a discontinuous gradient of Histopaque 1119 (4 ml) and Histopaque 1077 (5 ml) from Sigma. The gradient was centrifuged for 30 min at 700g with the brake off. The neutrophil layer between the Histopaque 1077 and 1119 was collected and washed in PBS 0.5% BSA. RBC lysis was performed as described earlier. Neutrophils were washed in PBS 0.5% BSA, counted and resuspended according to the experimental condition. Alternatively, blood was sedimented in a saline solution containing 1.25% dextran and neutrophils were negatively selected with magnetic beads 33 . Neutrophil purity, as assessed by the hemocytometer, was always higher than 93%. Bone marrow neutrophil and mononuclear cell isolation. To reach reasonable amounts of protein, all the western blot analyses in mice were performed on neutrophils isolated from bone marrows. Mice were killed by cervical dislocation. Femurs and tibias were collected in cold sterile Hank balanced salt solution (HBSS; Invitrogen) and flushed with HBSS 0.25% BSA. Cells were layered on top of a discontinuous gradient of Percoll 81%, 62%, 55%, freshly prepared and centrifuged for 30 min at 2,000g with the brake off. Monocytes were collected at the interface between the bone marrow cells and the layer of Percoll 55%, whereas neutrophils were collected at the interface between Percoll 55% and 62%. Cells were washed in HBSS 0.25% BSA and RBC lysis was performed as described earlier. Neutrophils (or monocytes) were washed again, counted and resuspended according to the experimental setting. Neutrophil (or monocyte) purity, as assessed using a haemocytometer, was higher than 87%. FACS analysis and flow sorting of blood or tumour-associated cells. Blood was collected in 10% heparin, incubated for 15 min with Mouse BD Fc Block (2.4G2, BD Pharmingen) 1:100 and stained for 20 min at room temperature. After RBC lysis, cells were washed and resuspended in FACS buffer (PBS containing 2% FBS and 2 mM EDTA). Tumours were minced in RPMI medium containing 0.1% collagenase type I and 0.2% dispase type I (Gibco) for 30 min at 37 uC and passed through a 70 and 40 mm cell strainer. After RBC lysis, cells were resuspended in FACS buffer. Lungs were collected after 7 min of transcardial perfusion with saline and processed as for the tumours. Single-cell suspensions were incubated for 15 min at 4 uC with Mouse BD Fc Block 1:100 in FACS buffer. The antibodies were added directly in the blocking solution in the appropriate combinations (as indicated in the figure legends). CD45 (30F-11), CD11b (M1/70), Ly6G (1A8), CD45R (RA3-6B2), CD3 (17A2), CD4 (RM4-5), IgE (R35-72), CD49b (DX5), Ly6C (AL-21) (all from BD Pharmingen), F4/80 (BM8), CD115 (AF598), MHCII (M5/114.15-12) (all from eBioscience), were used 1:200 for 2 3 10 6 in 100 ml; Siglec-F (E50-2440, BD Pharmingen) was diluted 1:750. In all the stainings 7AAD (BD Pharmingen) was used to gate out dead cells. For intra-tumour proliferation, 1 mg of BrdU was i.p. injected in each mouse 4 h before tumour collection and cell proliferation was quantified on single-cell suspensions with the FITC BrdU Flow Kit (BD Bioscience) according to the manufacturer's protocol. Tumour apoptosis was assessed by staining single-cell suspensions for the apoptotic marker AnnexinV (1:40, BD Bioscience), excluding 7AAD-positive cells. For TAN apoptosis, tumour single-cell suspensions were gated for CD11b (M1/70) and Ly6G (1A8); AnnexinV and 7ADD were used to distinguish apoptotic or dead neutrophils. In vitro neutrophil apoptosis was performed by seeding neutrophils isolated from tumour-bearing mice at a concentration of 1 3 10 6 per ml and stimulating them with or without LPS (1 mg ml 21 ), alone or in combination with HGF (100 ng ml 21 ) for 10 h at 37 uC. Cells were collected, washed and stained for AnnexinV and 7AAD. The combination of CD11b (M1/70), Ly6G (1A8) and MET (eBioclone 7, eBioscience, 1:50) was used to identify triple-positive MET-expressing neutrophils in blood or 7AAD-negative single-cell suspensions from tumours. Freshly stained samples were analysed by FACS Canto II (BD Bioscience). For tumour-associated neutrophil sorting, the myeloid population was enriched by coating with CD11bconjugated magnetic beads (MACS, Miltenyi Biotec), followed by separation through magnetic columns (MACS, Miltenyi Biotec), staining with Ly6G and sorting with a FACS Aria I (BD Bioscience). Cells were collected in RLT buffer (Qiagen) for RNA extraction or resuspended according to the experimental conditions. Human neutrophil isolation. Ten millilitres of venous blood from healthy volunteers were collected in citrate-coated tubes and isolated by erythrocyte sedimentation with dextran and purification with a discontinuous plasma-Percoll gradient as already described 34 . Lung cancer patients. We enrolled four non-small-cell lung carcinoma patients with no previous history of oncological, chronic inflammatory, or autoimmune diseases within 10 years before this study. This patient list includes 2 males (61 and 71 years of age) and 2 females (64 and 68 years of age), of which 3 were smokers (1 T1N0M0 adenocarcinoma, 1 T2N0M0 large-cell carcinoma, 1 T3N0M0 squamous-cell carcinoma) and 1 was a non-smoker (T2N0M0 adenocarcinoma). The protocol was approved by the Ethics Committee of the University Hospitals Gasthuisberg (Leuven), and all subjects consented before study participation. Flow sorting of neutrophils from lung cancer patients. Lung tumour biopsies or healthy tissues were minced in RPMI medium containing 0.1% collagenase type I, 0.2% dispase type I and DNase I 100 U ml 21 (60 min at 37 uC), passed through a 19 G needle and passed through a 70 and 40 mm cell strainer. After RBC lysis, cells were resuspended in FACS buffer (PBS containing 2% FBS and 2 mM EDTA) and counted. The myeloid population, enriched using CD11b-conjugated magnetic beads (MACS, Miltenyi Biotec) and separated through a magnetic column (MACS, Miltenyi Biotec), was stained with anti-CD66b (G10F5, BD Pharmingen, 1:100) for 20 min at 4 uC and sorted with FACS Aria I (BD Bioscience). Cells were counted and resuspended in RLT buffer (Qiagen) for RNA extraction. Endothelial cell isolation. Lungs were collected and a single-cell suspension was obtained as described earlier. Endothelial cells were obtained by performing a negative selection for CD45 (30F-11) and F4/80 (CI:A3-1) followed by a positive selection for CD31 (MEC 13.3) by using magnetic beads (Dynabeads, Invitrogen) according to the manufacturer's protocol. Peritoneal macrophages. Five millilitres of sterile PBS were injected in the peritoneum of anaesthetized mice and collected after 3 min. Cells were centrifuged, washed and cultured overnight. TCM and LLC (or A549) CCM preparation. Two grams of end-stage LLC tumour explanted from WT mice were chopped and incubated at 37 uC in 7 ml of DMEM (supplemented with 2 mM glutamine, 100 units ml 21 penicillin/100 mg ml 21 streptomycin) FBS-free (DMEM 0% FBS). 5 3 10 4 LLC (or A549) were seeded in a 6-multiwell plate in DMEM 10% FBS and incubated at 37 uC. Medium alone (DMEM 0% FBS or DMEM 10% FBS, respectively) was used to prepare mock controls. After 72 h, the medium was filtered, supplemented with 2 mM glutamine and 20 mM HEPES and stored at 220 uC. TCM and mock medium (DMEM 0% FBS) were diluted 1:5 in DMEM 10% FBS; CCM and mock medium (DMEM 10% FBS) were diluted 4:5 in DMEM FBS-free. qRT-PCR. For mRNA analysis, 1 3 10 5 or 3 3 10 5 mouse or human blood neutrophils, respectively, were incubated in normoxic (21% oxygen) or hypoxic (1% oxygen) conditions, or stimulated with TCM (plus 50 mg ml 21 Enbrel or human IgG where indicated), CCM, A549-CCM, 100 ng ml 21 of murine or human TNFa, 50 ng ml 21 LPS, or mock medium in a 96-multiwell plate for 4 h at 37 uC. For NF-kB inhibition, 0.18 3 10 6 neutrophils were pre-treated with 10 mM 6-amino-4-(4-phenoxyphenylethylamino) quinazoline (Calbiochem) for 1 h at 37 uC and stimulated with 100 ng ml 21 of murine TNF-a for 1 h at 37 uC. 2 3 10 5 HUVECs were seeded in a 24-multiwell plate coated with 0.1% gelatin and stimulated with 5 ng ml 21 IL-1a in DMEM 10% FBS for 4 h at 37 uC. Cells were washed in PBS, collected in RLT buffer (Qiagen) and kept at 280 uC. RNA was extracted with the RNeasy Micro kit (Qiagen) according to the manufacturer's instructions. Reverse transcription to cDNA was performed with the SuperScript III First Strand cDNA Synthesis Kit (Life Technologies) according to the manufacturer's protocol. Premade assays were purchased from Applied Biosystem, except for Nos2 that was provided by IDT. cDNA, primer/probe mix and TaqMan Fast Universal PCR Master Mix were prepared in a volume of 10 ml according to manufacturer's instructions (Applied Biosystems). Samples were loaded into an optical 96-well Fast Thermal Cycling plate (Applied Biosystems) and qRT-PCR were performed using an ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems) ELISA. To quantify plasma, intra-tumoural, tumour-released (TCM) and neutrophil-released HGF, a murine HGF ELISA kit (R&D) was used according to manufacturer's protocols. Blood was collected from tumour-free or tumour-bearing mice and plasma was prepared according to manufacturer's instruction. TCM was prepared as described earlier. Tumour proteins were extracted in Extraction Buffer (20 M Tris HCl, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA). 0.2 3 10 6 neutrophils were cultured for 20 h in DMEM complete in LETTER RESEARCH presence or absence of 100 ng ml 21 of murine TNF-a. Medium was collected, spun down and supernatant stored at 280 uC until use. Mock medium was used as negative control. For phospho-MET quantification, 6 3 10 6 mouse blood neutrophils isolated from tumour-bearing mice were cultured in the presence or absence of 100 ng ml 21 of murine TNF-a; 11 h later, cells were stimulated or not with 100 ng ml 21 of mouse HGF in the presence of 1 mM orthovanadate for 3 min at 37 uC, washed in PBS supplemented with 1 mM orthovanadate and 13 phosStop (Roche) and lysed in Extraction Buffer supplemented with 1 mM orthovanadate, 23 phosStop and Complete Mini protease inhibitor cocktail (Roche) for 20 min at 4 uC. After clearance, samples were quantified and the same amount of proteins was used for MET and phospho-MET detection using a sandwich ELISA. Briefly, 96-well microtitre plates (MaxiSorp, Nunc) were coated with 1 mg ml 21 of antimouse MET antibody (AF527, R&D Systems) overnight at 4 uC and then incubated for 2 h at room temperature in blocking buffer (PBS, 0.1% Tween-20, 6% non-fat dry milk). The same amount of proteins per sample was diluted in blocking buffer and incubated for 2 h at room temperature on the ELISA plate. After 6 washes in PBS 0.1% Tween-20, samples were incubated for 2 h at room temperature with the mouse anti-MET (3D4, Invitrogen) or the mouse anti-phosphotyrosine (4G10, Merck Millipore) antibodies diluted 1:500 in blocking buffer, then washed 6 times in PBS 0.1% Tween-20, and incubated with goat anti-mouse immunoglobulins conjugated to horseradish peroxidase (sc-2031, Santa Cruz Biotechnology) diluted 1:500 in blocking buffer for 2 h at room temperature. Signals were developed by 15 min incubation with the 3,39,5,59-tetramethylbenzidine (TMB) substrate solution (Promega). After stopping the reaction with H 2 SO 4 , absorbance was measured at 450 nm and corrected for 630 nm with a spectrophotometer. Western blot. To assess MET deletion, bone marrow cells, neutrophils, peritoneal macrophages, monocytes (all cultured overnight in TCM) or endothelial cells were lysed in hot Laemmli buffer (2.5% SDS, 25% Tris-HCl pH 6.8) for 10 min at 96 uC, sonicated, cleared and quantified. Alternatively, 2 3 10 6 bone-marrow-derived neutrophils from WT mice were stimulated with TCM, CCM, 100 ng ml 21 of murine TNF-a (or mock medium 0% FBS or 10% FBS as control) for 20 h at 37 uC. For the co-culture with HUVECs, a monolayer of HUVECs was stimulated for 4 h with 5 ng ml 21 IL-1a at 37 uC, and washed before neutrophil seeding. After 20 h of stimulation, neutrophils were collected using Cell Dissociation Buffer Enzyme Free PBS-Based (Gibco). Cells were washed in PBS, lysed in 15 ml of a protease inhibitor mixture and incubated for 15 min on ice. The protease inhibitor mixture was obtained by dissolving one tablet of Complete Mini protease inhibitor mixture (Roche) in 5 ml of PBS with 2 mM diisopropyl fluorophosphate (DFP; Acros Organics). After addition of an equal amount of 23 SDS sample buffer supplemented with 4% 2-mercaptoethanol, the lysates were boiled for 15 min and kept at 280 uC until use. NF-kB inhibition was achieved by pre-treating 7 3 10 6 neutrophils with 10 mM 6-amino-4-(4-phenoxyphenylethylamino) quinazoline (Calbiochem) for 1 h at 37 uC; cells were then stimulated with murine TNF-a (100 ng ml 21 ) for 5 h before lysis. Human MET was assessed by stimulating 3 3 10 7 blood neutrophils isolated from the blood of healthy volunteers with A549-CCM, 100 ng ml 21 human TNF-a, 50ngml 21 LPS (or mock medium 10% FBS as control) for 20 h. Cells were incubated with 2.7 mM DFP for 15 min at 4 uC, collected and washed in PBS supplemented with 2.7 mM DFP and Complete Mini protease inhibitor 13, and lysed in hot Laemmli buffer at 96 uC for 10 min. Cell lysates were sonicated, cleared and quantified. 63 loading buffer was added before loading on the gel. The following primary antibodies were used: mouse anti-mouse Met (3D4, Invitrogen), mouse anti-mouse b-actin (I-19, Santa Cruz), mouse anti-vinculin (hVIN-1, Sigma), rabbit anti-human MET (D1C2, Cell Signaling), horseradish peroxidase (HRP)-conjugated anti-b-tubulin (Abcam). The following secondary antibodies were used: HRP-conjugated goat anti-mouse and HRP-conjugated goat anti-rabbit (Santa Cruz). Signal was visualized by Enhanced Chemiluminescent Reagents (ECL; Invitrogen) or West Femto by Thermo Scientific according to the manufacturer's instructions. Adhesion assay. 4 3 10 4 HUVECs were seeded in M199 complete in a 96-multiwell plate, previously coated with 0.1% gelatin. After 12 h, HUVECs were stimulated with 5 ng ml 21 IL-1a in DMEM 10% FBS at 37 uC. After 4 h the endothelial monolayer was gently washed and 2.5 3 10 5 WBCs were isolated indistinctly from Tie2;Met wt/wt and Tie2;Met fl/fl mice or from WTRWT and KORWT transplanted mice, were seeded on top of it, with or without murine HGF (50 ng ml 21 ). After 15 min non-adherent cells were washed out whereas adherent cells were detached by using a Cell Dissociation Buffer Enzyme Free PBS-Based (Gibco). Cells were stained for Ly6G (clone 1A8), washed and resuspended in PBS-BSA 0.1% with unlabelled counting beads (BD Bioscience) and quantified by FACS Canto II (BD Bioscience). Transmigration and migration assay. For the transmigration assay, 2 3 10 5 HUVECs were seeded on 3 mm polycarbonate membrane (Transwell; Costar) previously coated with 0.1% gelatin in M199 complete. After 12 h, HUVECs were stimulated for 4 h at 37 uC in DMEM 10% FBS with 5 ng ml 21 IL-1a and then washed. 5 3 10 5 WBCs isolated indistinctly from Tie2;Met wt/wt and Tie2;Met fl/fl mice or from WTRWT and KORWT transplanted mice were seeded on top of the endothelial monolayer, while mock medium, TCM (with or without 3 mg ml 21 anti-HGF antibody AF-2207; R&D) 18, 31 or 50 ng ml 21 murine HGF was added in the bottom. After 2 h at 37 uC, transmigrated cells were collected from the bottom chambers and from the lower side of the filter with cold PBS 0.5% EDTA. Cells were stained and Ly6G 1 cells were quantified as described earlier. In the migration assays WBCs were seeded directly on top of 3 mm polycarbonate porous membranes. Nitric oxide measurement by FACS. Neutrophils isolated from the blood of WT or KO LLC-tumour bearing mice were co-cultured for 4 h with LLC shMet, washed and resuspended in 20 mM HEPES-PBS, and incubated for 10 min with 5 mM DAF-FM diacetate (Molecular Probes) in the absence or presence of mouse HGF (100 ng ml 21 ) at 37 uC. Cells were then washed and analysed by FACS. Cytotoxicity assay. LLC shMet or T241 shMet were transduced with a luciferaseexpressing lentiviral vector (EX-hLUC-Lv114 from GeneCopoeia); 10 4 cells were then seeded in DMEM 10% FBS in a 96-multiwell plate. After 4 h, 0.2 3 10 6 neutrophils purified from the blood of tumour-bearing mice or directly from the tumours themselves, were co-cultured with the cancer cells in DMEM 2% FBS for 4 h at 37 uC, with or without 100 ng ml 21 mouse HGF or 1 mM L-NMMA (Sigma). After washing, adherent cells were lysed in 0.2% Triton, 1 mM dithiothreitol (DTT). Luciferase signal was revealed with a microplate luminometer. The use of shMet was thought to prevent any possible confounding activity of MET on cancer cell survival and thus to restrict the effect of HGF to neutrophils only. Histology and immunostainings. To obtain serial 7-mm-thick sections, tissue samples were immediately frozen in OCT compound or fixed in 2% PFA overnight at 4 uC, dehydrated and embedded in paraffin. Paraffin slides were first rehydrated to proceed further with antigen retrieval in citrate solution (DAKO). Cryosections were thawed in water and fixed in 100% methanol. If necessary, 0.3% H 2 O 2 was added to methanol to block endogenous peroxidases. The sections were blocked with the appropriate serum (DAKO) and incubated overnight with the following antibodies: rat anti-CD45 (30F-11, BD Pharmingen) 1:100, rat anti-Ly6G (1A8, BD Pharmingen) 1:100, rat anti-CD31 (MEC 13.3, BD Pharmingen) 1:200, rabbit anti-FITC (Serotec) 1:200, goat anti-phosphohistone H3 (Cell Signaling) 1:100, rat anti-F4/80 (CI:A3-1, Serotec) 1:100, mouse anti-NK1.1-biotin (PK136, BD Pharmingen) 1:200, rat anti-CD45R (RA3-6B2, BD Pharmingen) 1:100, rat anti-CD4 (H129.9, BD Pharmingen) 1:100, rat anti-CD8 (53-6.72, BioXCell) 1:100, hamster anti-CD11c biotin (N418, eBioscience) 1:100, mouse anti-3-nitrotyrosin (HM.11 Santa Cruz) 1:200. Appropriate secondary antibodies were used: Alexa488-or Alexa568-conjugated secondary antibodies (Molecular Probes) 1:200, HRP-labelled antibodies (DAKO) 1:100, Biotin-labelled antibodies (Jackson ImmunoResearch) 1:100. When necessary, tyramide signalling amplification (Perkin Elmer, Life Sciences) was performed according to the manufacturer's instructions. Whenever sections were stained in fluorescence, ProLong Gold mounting medium with DAPI (Invitrogen) was used. Otherwise, 3,39-diaminobenzidine was used as a detection method followed by Harris' haematoxilin counterstaining, dehydration and mounting with DPX. Apoptotic cells were detected by the TUNEL method, using the AptoTag peroxidase in situ apoptosis detection kit (Millipore) according to the manufacturer's instructions. For the double staining TUNEL and Ly6G, TUNEL staining was performed as described earlier, followed by Ly6G staining by using the Vectastain ABC kit (Vector Laboratories) according to the manufacturer's instructions. Tumour necrosis and lung metastasis were evaluated by H&E staining. Necrotic area was defined as the area including necrotic cancer cells, inflammatory cells and stromal cells, compared to the total area of the field. Necrotic cells display a more glassy homogeneous appearance in the cytoplasm with increased eosinophilia, while the nuclear changes are reflected by karyolysis, pyknosis and karyorrhexis. Alternatively, the necrotic tissue was visualized by autofluorescence as previously described 35 . Microscopic analysis was done with an Olympus BX41 microscope and Cell Sense imaging software or a Zeiss Axioplan microscope with KS300 image analysis software. The morphometric analysis was performed by acquiring 4-6 fields per section on five independent sections (at a distance of 40 mm in depth during sectioning) from the same biological tissue sample. The values in the graphs represent the average of the means of at least five samples and the standard error indicates the variability among the different samples. Hypoxia assessment and tumour perfusion. Tumour hypoxia was detected by injection of 60 mg kg 21 pimonidazole into tumour-bearing mice 1 h before tumour harvesting. To detect the formation of pimonidazole adducts, tumour cryosections were immunostained with Hypoxyprobe-1-Mab1 (Hypoxyprobe kit, Chemicon) following the manufacturer's instructions. Perfused tumour vessels were counted on tumour cryosections from mice injected intravenously with 0.05 mg fluorescein isothiocyanate (FITC)-conjugated lectin (Lycopersicon esculentum; Vector Laboratories).
Tumour-derived nitric oxide production. LLC tumours were collected 8 days after injection, cut in pieces of about 5 3 5 mm, weighted and incubated at 37 uC in a 24-multiwell plate with 800 ml of DMEM. After 24 h, the media was collected, centrifuged to remove cell debris, and NO levels were measured using the Griess reagent system kit (Promega). Statistics. Data entry and all analyses were performed in a blinded fashion. All statistical analyses were performed using GraphPad Prism software. Statistical significance was calculated by two-tailed unpaired t-test on two experimental conditions or two-way analysis of variance (ANOVA) when repeated measures were compared, with P , 0.05 considered statistically significant. Data were tested for normality using the D'Agostino-Pearson omnibus test (for n . 8) or the Kolmogorov-Smirnov test (for n # 8) and variation within each experimental group was assessed. Detection of mathematical outliers was performed using the Grubbs' test in GraphPad. Sample sizes for all experiments were chosen based on previous experiences. Independent experiments were pooled and analysed together whenever possible as detailed in figure legends. All graphs show mean values 6 s.e.m. 
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Extended Data Figure 1 | Scheme illustrating the role of MET in neutrophils. During cancer or infections, the release of cytokines such as IL-1 at the inflammatory site will promote the expression of TNF-a on the endothelium and the surrounding tissue. When circulating neutrophils encounter the activated endothelium, TNF-a will unleash NF-kB through binding to TNFR1, which in turn will induce MET expression on the neutrophil surface. HGF, also released and proteolytically activated at the site of inflammation, will bind to MET and stimulate the firm adhesion of neutrophils to the endothelium, probably via integrin engagement, and thus neutrophil diapedesis. Once extravasated, the HGF/MET pathway will still function on neutrophils by reinforcing their cytotoxic response through the induction of iNOS and NO production, ultimately favouring a bactericidal and tumoricidal neutrophil phenotype. prevents the recruitment of anti-tumoural neutrophils to several neoplastic tissues and inflammatory sites. a, Tumour weight of subcutaneous B16F10 melanomas in WTRWT and KORWT mice. Data combine two independent experiments; total n: WTRWT, 8; KORWT, 9. b, c, Total tumour weight (b) and metastatic index (c) in MMTV-PyMT mice reconstituted with WT or Met KO bone marrow cells before tumour appearance (WTRPyMT and KORPyMT mice, respectively). Data combine three independent experiments; total n: WTRPyMT, 13; KORPyMT, 16. d, e, FACS quantification for CD11b 1 Ly6G 1 neutrophils in T241 tumours harvested from WTRWT or KORWT mice (d) or in in breast tumours spontaneously grown in WTRPyMT and KORPyMT mice (e). Data combine two independent experiments; total n 5 10 mice per condition (d) or total n 5 8 mice per condition (e). f-i, Length measurement (f) and representative image (g) of the colon, as well as quantification of neutrophils (h) and macrophages (i) on bowel sections, from WTRWT and KORWT mice upon induction of chronic colitis compared to healthy control. Data combine two independent experiments; total n: healthy, 5; WTRWT, 12; KORWT, 15. j, k, Tumour weight (j) and metastatic mesenteric lymph nodes (k) 12 days after orthotopic injection of pancreatic Panc02 cancer cells in WTRWT and KORWT mice. Data combine two independent experiments; total n 5 12 per condition. l, Histological quantification of Ly6G 1 infiltrates in Panc02 pancreatic tumours harvested from WTRWT and KORWT mice. Data combine two independent experiments; total n 5 12 mice per condition. m, Quantification of plasma HGF in tumour (TM)-free mice, in subcutaneous LLC or orthotopic Panc02 tumourbearing mice. Data combine two independent experiments; total n: tumour free, 10; LLC, 10; Panc02, 8 biological replicates. n, Quantification of HGF in subcutaneous LLC or orthotopic Panc02 tumours. Data combine two independent experiments; total n: LLC, 10; Panc02, 8 biological replicates. o, p, Quantification of HGF in plasma (o) or in subcutaneous LLC tumours (p) from tumour-bearing WTRWT and KORWT mice. Data are representative of two independent experiments using 5 mice per condition per experiment. q, Quantification of Ly6G 1 area on sections from B16F10 melanomas grown in C57BL/6 WT mice, daily treated with PF-04217903, INCB28060, JNJ-38877605, or vehicle as control. Data combine two independent experiments; total n: vehicle, 14; PF-04217903, 9; INCB28060, 6; JNJ-38877605, 4. r, Western blot analysis for MET in B16F10 melanoma cells after transduction with a lentiviral vector encoding scrambled or mouse shMet under a constitutive promoter; vinculin was used as loading control. Western blot is representative of three independent repetitions. Western blot images have been cropped for presentation. Full scan images are shown in Supplementary Fig. 1 . *P , 0.05 versus WTRWT (a, d, h), versus WTRPyMT (b, e), versus LLC (m, n), versus vehicle (q); {P , 0.05 versus healthy (f, h, i), versus tumour free (m). Scale bar: 10 mm (g). All graphs show mean 6 s.e.m. . Data combine two independent experiments; total n 5 8 biological replicates per condition. f, g, ELISA for total MET (f) and phospho-MET (g) from mouse neutrophils stimulated for 3 min with mock medium or HGF after an overnight incubation with or without TNF-a. Data combine three independent experiments; total n 5 6 biological replicates per condition. h, HGF release by neutrophils stimulated with mock medium or TNF-a after 20 h in culture. Data combine two independent experiments; total n 5 6 biological replicates per condition. i, qRT-PCR for TNFA in HUVECs upon stimulation with IL-1a compared to mock medium. Data combine two independent experiments; total n 5 4 biological replicates per condition. j, qRT-PCR for Met in mouse neutrophils co-cultured with HUVEC/NS or HUVEC/IL transduced with shTNFA or scramble as control. Data are representative of three independent experiments in which three different shRNA sequences were used; total n 5 4 biological replicates per condition per experiment. k, l, qRT-PCR for Met in WT, TNFR1 KO or TNRF2 KO neutrophils upon co-culture with HUVEC/NS or HUVEC/ IL (k), or after stimulation with conditioned medium (TCM) from LLC tumours (l). Data are representative of two independent experiments using four biological replicates per condition per experiment. m, qRT-PCR for MET in human neutrophils stimulated with A549-CCM in the presence or absence of Enbrel or human IgG as control. Data are representative of two independent experiments using four biological replicates per condition per experiment. *P , 0.05 versus mock (b, c, i), versus TNF-a alone (g), versus HUVEC/NS (j), versus WT (k, l), versus A549-CCM (m); {P , 0.05 versus untreated or HGF alone (f, g), versus HUVEC/NS (k), versus mock (l, m). Graph shows mean 6 s.e.m. 
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